Format

Send to

Choose Destination
Cancer J. 2015 Nov-Dec;21(6):475-9. doi: 10.1097/PPO.0000000000000155.

Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity.

Author information

1
From the *Division of Hematology/Oncology, Department of Medicine, and †Abramson Cancer Center; and ‡Departments of Pathology and Laboratory Medicine, and Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Abstract

The durable remission of B-cell leukemia and lymphoma following chimeric antigen receptor (CAR) T-cell therapy has brought this new form of adoptive immunotherapy to center stage with the expectation that CAR T-cell therapy may provide similar efficacy in other hematologic and solid cancers. Herein, we review recent advances in the areas of CAR design that improve CAR T-cell proliferation, engraftment, and efficacy, as well as clinical application strategies that are designed to improve clinical efficacy while reducing the risk of toxicity and broaden patient access to this promising form of cancer immunotherapy.

PMID:
26588679
PMCID:
PMC4656124
DOI:
10.1097/PPO.0000000000000155
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center